In8bio Inc Total Assets
In8bio Inc total assets. Based on the latest financial reports, In8bio Inc (INAB) holds total assets worth $21.75 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INAB stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of In8bio Inc (2018–2025)
Total assets of In8bio Inc from 2018 to 2025. This chart illustrates how In8bio Inc's total assets have evolved over time, based on quarterly financial data. See INAB stock price for real-time trading data and today's change.
In8bio Inc - Asset Composition Analysis
In8bio Inc Total Assets Breakdown (December 2025)
In8bio Inc total assets breakdown as of December 2025. In8bio Inc's total assets of $21.75 Million consist of 86.4% current assets and 13.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how In8bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore INAB current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: In8bio Inc's current assets represent 86.4% of total assets in 2025, an increase from 86.0% in 2018.
- Cash Position: Cash and equivalents constituted 83.9% of total assets in 2025, down from 84.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
In8bio Inc Competitors by Total Assets
Key competitors of In8bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
In8bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.21 | 7.03 | 20.31 |
| Quick Ratio | 8.21 | 7.03 | 20.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.24 Million | $11.79 Million | $41.72 Million |
In8bio Inc - Advanced Valuation Insights
This section examines the relationship between In8bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.61 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 54.1% |
| Total Assets | $32.28 Million |
| Market Capitalization | $9.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values In8bio Inc's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: In8bio Inc's assets grew by 54.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for In8bio Inc (2018–2025)
The table below shows the annual total assets of In8bio Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $32.28 Million | +54.13% |
| 2024-12-31 | $20.94 Million | -37.87% |
| 2023-12-31 | $33.71 Million | +2.03% |
| 2022-12-31 | $33.04 Million | -21.75% |
| 2021-12-31 | $42.22 Million | +101.93% |
| 2020-12-31 | $20.91 Million | +1750.44% |
| 2019-12-31 | $1.13 Million | -80.83% |
| 2018-12-31 | $5.89 Million | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more